EligibleTrials

Clinical trials recruiting for Epithelial Ovarian Cancer

10
Recruiting trials
23
US states with sites
7
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 9Phase 2 5

Drugs and treatments being studied

InterventionTrials
68Ga-FAPi-461
AVZO-0211
Abemaciclib1
BCA1011
Biological NI-18011
CRX100 suspension for infusion1
CT-951
Carboplatin1
Cyclophosphamide1
ETX-194771
Fludarabine1
Fulvestrant1

Where trials are recruiting (top US states)

StateRecruiting trials
Texas5
Ohio4
Pennsylvania4
Florida3
New York3
Arizona2
California2
Connecticut2
Illinois2
Massachusetts2
Tennessee2
Virginia2

Top cities

Cleveland, Ohio 3New York, New York 3Philadelphia, Pennsylvania 3Boston, Massachusetts 2Chicago, Illinois 2Dallas, Texas 2Fairfax, Virginia 2Houston, Texas 2La Jolla, California 2Nashville, Tennessee 2

Self-screener

Recruiting trials

Related conditions

Trials recruiting for Epithelial Ovarian Cancer often also study these conditions. Each links to its own recruiting-trial list.

Pancreatic cancer 870Colorectal cancer 1359Lung cancer 2180Breast cancer 2239Gastric cancer 91Triple-negative breast cancer 138Ovarian cancer 118Endometrial cancer 68TNBC - Triple-Negative Breast Cancer 35Stomach Neoplasms 11

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Epithelial Ovarian Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.